scholarly journals Jumlah Trombosit pada Mencit Diabetes setelah Pemberian Ekstrak Rumput Laut Merah (Rhodophyceae)

2020 ◽  
Vol 7 (3) ◽  
pp. 171
Author(s):  
Dahna Maudita Kartikasari ◽  
Didin Erma Indahyani ◽  
Depi Praharani

Oxidative stress in diabetes mellitus triggers activation and increases in platelet counts that play a role in the formation of platelet plugs in the blood clotting process. If excessive blood clots occur, there is a risk of cardiovascular disease. Red seaweed extract contains carotenoids, phenols and their derivatives, fikobilin pigments, polysaccharide sulfates, and vitamins. The biggest phenol compound is flavonoids which are compounds that can produce platelet antia-gregation effects. The purpose of this study was to examine the effect of giving red seaweed extract to platelet counts in diabetic mice. The study group consisted of the treatment group of red seaweed extract, normal control, positive control and negative controls. The dosage of seaweed extract as much as 10 mg / 20 grBB is given in condition. The calculation of platelet count is carried out directly with the Brecher Cronkite method using a calculated room Improved Neubauer. The One Way ANOVA test results showed a significance value (p <0.05), that is, the group of diabetic mice given red seaweed extract had a lower platelet count of 280000 μl compared to diabetic mice given metformin as much as 379000 μl. The decrease is due to flavonoids, saponins, alkaloids, β carotene, vitamins and minerals able to stabilize the production of megakaryocytes and platelets, prevent the destruction of pancreatic β cells and prevent free radicals. It was concluded that red seaweed extract can reduce platelet counts of diabetic mice near normal values.

1975 ◽  
Author(s):  
John Das ◽  
Dianna Ausprunk ◽  
Judah Folkman

Endotoxin-like activity (ELA) can be detected in platelets in human Gram-negative sepsis1. With our photometric version of the Limulus test, we quantified the ELA of platelets in 12 children with gastroenteritis of Gram-negative origin. 5 severe cases had thrombocytopenia (41 × 103/μl), and an ELA-equivalent of 10.4 ± 6.9 ng in platelets from 1 ml PRP; 4 died of DIC. 7 patients wore moderately ill, with platelets 138 × 103/μl, and an ELA of 5.3 ± 3.9 ng. In fi controls with a background platelet-ELA of 1.9 ng, incubation with endotoxin (50 ng/ml PRP) raised the ELA by 3 ng. In the one infant surviving severe enteritis, a similar incubation raised the platelet-ELA by 16 ng, the platelet count being 26 × 103/μl. In DIC, we routinely find platelet-ELA at 20 ng and platelet counts of 25 χ 103/μl. In in-vitro EM studies, endotoxin complexed with Cu2+ adhered to human platelet surfaces; pseudopods and degranulation were also seen along with fragmentation of endotoxin particles. The membrane changes suggested peroxidation.We postulate that endotoxin adheres to an activates human platelets to release materials with procoagulant properties in the Limulus test, and capable of precipitating DIC. As sensitized platelets are phagocytized by the RES, platelets may prove to be a system for clearing circulating endotoxin. 1 Das, Schwartz and Folkman: Surgery 74, 235, 1973.


2020 ◽  
Vol 11 (1) ◽  
pp. 51-57
Author(s):  
Yessy Velina ◽  
Nirva Diana ◽  
Aulia Annisa

Billygoat weed (Ageratum conyzoides) is mainly used to treat wounds and fever. People also do not understand the use of these leaves in the treatment to increase the platelet counts. The objectives of this research Objectives were to test whether the Billygoat Weed’s leaves can increase platelet count of male mice and to find out what is the most effective dose of the Billygoat Weed on the platelet count of male mice. This research was done by employing the true experimental approach with the completely randomized design which consisted of 5 treatments, namely the negative control (plain water), the positive control (acetylsalicylic acid), 1.68 mg/kgBW, 2.52 mg/kgBW, and 3.36 mg/kgBW on five mice in each treatment. The increase in the platelet counts, based on the results of One-Way ANOVA with a p-value of 0,0004, the Billygoat Weed extract was able to increase the platelet counts. Through further testing, the smallest significant difference showed that a dose of 3.36 mg/kgBW was effectively able to increase the platelet counts of male mice with an average of 11140.80/. Billygoat weed (Ageratum conyzoides) is mainly used to treat wounds and fever. People also do not understand the use of these leaves in the treatment to increase the platelet counts. The objectives of this research Objectives were to test whether the Billygoat Weed’s leaves can increase platelet count of male mice and to find out what is the most effective dose of the Billygoat Weed on the platelet count of male mice. This research was done by employing the true experimental approach with the completely randomized design which consisted of 5 treatments, namely the negative control (plain water), the positive control (acetylsalicylic acid), 1.68 mg/kgBW, 2.52 mg/kgBW, and 3.36 mg/kgBW on five mice in each treatment. The increase in the platelet counts, based on the results of One-Way ANOVA with a p-value of 0,0004, the Billygoat Weed extract was able to increase the platelet counts. Through further testing, the smallest significant difference showed that a dose of 3.36 mg/kgBW was effectively able to increase the platelet counts of male mice with an average of 11140.80/𝑚𝑚3.


Blood ◽  
1997 ◽  
Vol 89 (1) ◽  
pp. 155-165 ◽  
Author(s):  
Laurence A. Harker ◽  
Ulla M. Marzec ◽  
Andrew B. Kelly ◽  
Ellen Cheung ◽  
Aaron Tomer ◽  
...  

Abstract This report examines the effects on hematopoietic regeneration of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF ) (2.5 μg/kg/d) alone and in combination with recombinant human granulocyte colony stimulating factor (rHu-GCSF ) (10 μg/kg/d) for 21 days in rhesus macaques receiving intense marrow suppression produced by single bolus injections of hepsulfam (1.5 g/m2). In six hepsulfam-only control animals thrombocytopenia (platelet count <100 × 109/L) was observed between days 12 and 25 (nadir 39 ± 20 × 109/L on day 17), and neutropenia (absolute neutrophil count <1 × 109/L) occurred between days 8 and 30 (nadir 0.167 ± 0.120 × 109/L on day 15). PEG-rHuMGDF (2.5 μg/kg/d) injected subcutaneously into four animals from day 1 to day 22 following hepsulfam administration produced trough serum concentrations of 1.9 ± 0.2 ng/mL and increased the platelet count twofold over basal prechemotherapy levels (856 ± 594 × 109/L v baseline of 416 ± 88 × 109/L; P = .01). PEG-rHuMGDF alone also shortened the period of posthepsulfam neutropenia from 22 days to 12 days (P = .01), although the neutropenic nadir was not significantly altered (neutrophil count 0.224 ± 0.112 × 109/L v 0.167 ± 0.120 × 109/L; P < .3). rHu-GCSF (10 μg/kg/d) injected subcutaneously into four animals from day 1 to day 22 following hepsulfam administration produced trough serum concentrations of 1.4 ± 1.1 ng/mL, and reduced the time for the postchemotherapy neutrophil count to attain 1 × 109/L from 22 days to 4 days (P = .005). The postchemotherapy neutropenic nadir was 0.554 ± 0.490 × 109neutrophils/L (P = .3 v hepsulfam-only control of 0.167 ± 0.120 × 109/L). However, thrombocytopenia of <100 × 109 platelets/L was not shortened (persisted from day 12 to day 25), or less severe (nadir of 56 ± 32 × 109 platelets/L on day 14; P = .7 compared with untreated hepsulfam animals). The concurrent administration of rHu-GCSF (10 μg/kg/d) and PEG-rHuMGDF (2.5 μg/kg/d) in four animals resulted in postchemotherapy peripheral platelet counts of 127 ± 85 × 109/L (P = .03 compared with 39 ± 20 × 109/L for untreated hepsulfam alone, and P = .02 compared with 856 ± 594 × 109/L for PEG-rHuMGDF alone), and shortened the period of neutropenia <1 × 109/L from 22 days to 4 days (P = .8 compared with rHu-GCSF alone). Increasing PEG-rHuMGDF to 10 μg/kg/d and maintaining the 21-day schedule of coadministration with rHu-GCSF (10 μg/kg/d) in another four animals produced postchemotherapy platelet counts of 509 ± 459 × 109/L (P < 10−4compared with untreated hepsulfam alone, and P = .04 compared with 2.5 μg/kg/d PEG-rHuMGDF alone), and 4 days of neutropenia. Coadministration of rHu-GCSF and PEG-rHuMGDF did not significantly alter the pharmacokinetics of either agent. The administration of PEG-rHuMGDF (2.5 μg/kg/d) from day 1 through day 22 and rHu-GCSF (10 μg/kg/d) from day 8 through day 22 in six animals produced peak postchemotherapy platelet counts of 747 ± 317 × 109/L (P < 10−4 compared with untreated hepsulfam alone, and P = .7 compared with PEG-rHuMGDF alone), and maintained the neutrophil count < 3.5 × 109/L (P = .008 v rHu-GCSF therapy alone). Thus, both thrombocytopenia and neutropenia are eliminated by initiating daily PEG-rHuMGDF therapy on day 1 and subsequently adding daily rHu-GCSF after 1 week in the rhesus model of hepsulfam marrow suppression. This improvement in platelet and neutrophil responses by delaying the addition of rHu-GCSF to PEG-rHuMGDF therapy demonstrates the importance of optimizing the dose and schedule of cytokine combinations after severe myelosuppressive chemotherapy.


Animals ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. 347
Author(s):  
Emma Strous ◽  
Arne Vanhoudt ◽  
Anja Smolenaars ◽  
Gerdien van Schaik ◽  
Matthijs Schouten ◽  
...  

Platelet and leukocyte count reference intervals (RIs) for cattle differ by age and while adult RIs are known, RIs for calves are studied less. The aims of this observational study are to evaluate variation of platelet counts of Holstein Friesian calves over the first 14 days of life and to propose RIs for platelet and leukocyte counts of Holstein Friesian calves aged 0–60 days. In a longitudinal study, 19 calves were blood sampled 17 times, in the first 14 days of their lives. Blood was collected in a citrate blood tube and platelet counts were determined. We assessed the course of platelet counts. In a field study, 457 healthy calves were blood sampled once. Blood was collected in an EDTA blood tube and platelet and leukocyte counts were determined. The RIs were calculated by the 2.5 and 97.5 percentiles. Platelet counts started to increase 24 h after birth (mean platelet count 381 × 109/L ± 138 × 109/L) and stabilized after five days (mean platelet count 642 × 109/L ± 265 × 109/L). In calves up to six days of age, platelet counts were lower than in calves older than five days. In conclusion, the RIs of platelet and leukocyte counts in calves were wider in range than the RIs for adult cattle, therefore, calf specific RIs for platelet and leukocyte counts should be used. From 6 until 60 days of age, we propose an RI for platelet counts of 287–1372 × 109/L and for the first 60 days of life an RI for leukocyte counts of 4.0–18.9 × 109/L.


2000 ◽  
Vol 83 (03) ◽  
pp. 480-484 ◽  
Author(s):  
John James ◽  
Dianne Brown ◽  
Gordon Whyte ◽  
Mark Dean ◽  
Colin Chesterman ◽  
...  

SummaryThis is the first report of a method to assess the significance of numerical changes in the platelet count based upon a result exceeding the normal intra-individual variation in platelet numbers. Serial platelet counts from 3,789 subjects were analysed to determine the intra-individual variation in platelet numbers. A platelet count difference of 98 × 109/L in males was found to represent a change that would occur by chance in less than 1 in 1,000 platelet count determinations. Tables to determine the significance of platelet number variations, given N previous observations, are provided at two probability levels. The repeatability of the platelet count was calculated as 0.871 (males) and 0.849 (females) indicating that the heritability of platelet count is high and that the platelet count is predominantly genetically determined. A seasonal variation in platelet count was found with a ‘winter’ versus ‘summer’ difference of 5.10 × 109/L (males) and 5.82 × 109/L (females).


2013 ◽  
Vol 18 (1) ◽  
pp. 86-93
Author(s):  
Gustavo Antônio Martins Brandão ◽  
Rafael Menezes Simas ◽  
Leandro Moreira de Almeida ◽  
Juliana Melo da Silva ◽  
Marcelo de Castro Meneghim ◽  
...  

OBJECTIVE: To evaluate the in vitro ionic degradation and slot base corrosion of metallic brackets subjected to brushing with dentifrices, through analysis of chemical composition by Energy Dispersive Spectroscopy (EDS) and qualitative analysis by Scanning Electron Microscopy (SEM). METHODS: Thirty eight brackets were selected and randomly divided into four experimental groups (n = 7). Two groups (n = 5) worked as positive and negative controls. Simulated orthodontic braces were assembled using 0.019 x 0.025-in stainless steel wires and elastomeric rings. The groups were divided according to surface treatment: G1 (Máxima Proteção Anticáries®); G2 (Total 12®); G3 (Sensitive®); G4 (Branqueador®); Positive control (artificial saliva) and Negative control (no treatment). Twenty eight brushing cycles were performed and evaluations were made before (T0) and after (T1) experiment. RESULTS: The Wilcoxon test showed no difference in ionic concentrations of titanium (Ti), chromium (Cr), iron (Fe) and nickel (Ni) between groups. G2 presented significant reduction (p < 0.05) in the concentration of aluminium ion (Al). Groups G3 and G4 presented significant increase (p < 0.05) in the concentration of aluminium ion. The SEM analysis showed increased characteristics indicative of corrosion on groups G2, G3 and G4. CONCLUSION: The EDS analysis revealed that control groups and G1 did not suffer alterations on the chemical composition. G2 presented degradation in the amount of Al ion. G3 and G4 suffered increase in the concentration of Al. The immersion in artificial saliva and the dentifrice Máxima Proteção Anticáries® did not alter the surface polishing. The dentifrices Total 12®, Sensitive® and Branqueador® altered the surface polishing.


2021 ◽  
Vol 28 (4) ◽  
pp. 5-22
Author(s):  
V. A. Bessonov

The article discusses two groups of problems in Russian statistics that still have no viable solutions. The frst one - the state of the statistics interface – is the set of channels through which users obtain statistical information. The second – metadata status – is the information on how the indicators are constructed. The problems are considered from the standpoint of consumers of statistical information, performing tasks of analyzing economic dynamics.It is concluded that with the transition from traditional printed materials to statistical information systems, interface development has come to a standstill, and in the development of metadata, there is no compliance with any standards, uniformity, and consistency. In the author's opinion, these problems seriously hinder the improvement of all Russian statistics, being a kind of blood clots. When an interface becomes a bottleneck, the value of statistics to users decreases. The unsatisfactory state of metadata leads to the fact that consumers of statistical information are not always able to use it adequately, and the problems of statistical methodology are conserved.The causes of the problems are determined, on the one hand, by the complex history of domestic statistics (extended period of development in a planned economy and the specifcs of economic transformation), and, on the other hand, by the lack of effective feedback.The author considers possible approaches to addressing the problems. The expediency of creating groups of specialists in the structure of the statistical department on the main problem blocks, acting as points of growth and centers of competence, accumulating knowledge, mastering domestic and foreign experience, attracting representatives of the expert community, directing and controlling the activities to solve problems, is substantiated.


Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 2096-2096
Author(s):  
Eric Mou ◽  
Colin Murphy ◽  
Jason Hom ◽  
Lisa Shieh ◽  
Neil Shah

Introduction Platelets are transfused prophylactically to prevent hemorrhage in a variety of patient populations. However, guidelines indicate that prophylactic platelet transfusions in patients with platelet counts above 50k/uL are usually not indicated, with notable exceptions including those undergoing neurological or cardiac bypass surgery. Common minor procedures such as paracentesis, central line placement, and lumbar puncture have been safely performed at platelet counts below 50k/uL. Despite this evidence, our institution incurred approximately 10 million dollars (USD) in direct platelet costs in 2017, with nearly 40% of platelet transfusions are occurring when the patient's platelet count exceeded 50k/uL. Given the significant financial impact of, and potential adverse effects associated with inappropriate platelet transfusion, we implemented a best practice advisory (BPA) in our electronic medical record (EMR) in order to better characterize patterns of platelet transfusion orders in patients with platelet counts >50k/uL. Methods An EMR-embedded BPA was activated in the inpatient hospital setting of a large, tertiary care academic medical center on May 1, 2019, and triggered whenever a platelet transfusion order was placed on an admitted patient whose most recent documented platelet count was >50k/ul. To inform the comparative impact of BPA alerts on provider behavior, alerts were randomized at the patient level to trigger either in standard or silent fashion. For standard alerts, the BPA appeared on-screen, informing the provider that their platelet transfusion order was potentially inappropriate and citing supportive evidence. Providers had the option of following or overriding the alert (Figure 1). In case of alert override, a pre-specified or free text justification was requested. Pre-specified options included upcoming neurosurgery, cardiac bypass surgery, known qualitative platelet defects, or patients taking antiplatelet drugs. Charge data were based on charges for platelet transfusion orders as listed in the hospital charge master. Results From May 1, 2019 to July 30, 2019, the alert fired 181 times (Figure 2). Alerts were silently triggered in 64 (35%) cases. Of the 117 active alerts, 23 (20%) were followed and 94 (80%) were overridden. The most common reasons for alert override included prophylactic transfusions ahead of non-cardiac and non-neurosurgical operations (18%), upcoming cardiac bypass surgery (18%), qualitative platelet defects (12%), active central nervous system (CNS) bleeding (12%), and active non-CNS bleeding (7%). The estimated cost savings associated with followed alerts was $18,170 USD. Discussion Our BPA was effective in reducing instances of platelet transfusion orders by 20% over a three-month period, translating to an estimated annual savings of nearly $70,000 USD in hospital charges. Conversely, the 80% alert override rate indicates that platelet transfusion in patients with platelet counts >50k/uL remains common, occurring in a variety of contexts. Potentially appropriate reasons for platelet transfusions included orders in the setting of cardiovascular bypass surgery, active CNS bleeding, or qualitative platelet defects, representing circumstances in which platelet thresholds are often set higher than 50k/uL. Alternatively, 25% of alert overrides occurred in potentially inappropriate contexts, including patients undergoing non-cardiovascular/non-neurosurgical procedures and patients with non-CNS active bleeding, settings where routinely targeting a platelet threshold >50k/uL is not supported by evidence. As a result of our study's randomized design, future directions include comparative analyses between patient care encounters in which alerts were silently versus visibly triggered, allowing for rigorous determination as to whether providers' interaction with our BPA influences subsequent rates of potentially inappropriate platelet utilization as compared to a control group. Overall, our findings show that platelets are frequently ordered in potentially inappropriate settings, and that reducing these orders imparts significant financial savings. These results provide an impetus for interventions directed at educating providers on appropriate platelet ordering practices, in order to further reduce unnecessary expenditures and optimize patient care. Disclosures No relevant conflicts of interest to declare.


2020 ◽  
Vol 16 (02) ◽  
pp. 86
Author(s):  
Margareta Retno Priamsari ◽  
Rina Ayu Krismonikawati

ABSTRACT Inflammation is a normal response to injury due to release of chemical mediators such as prostaglandins. Solanum betaceum Cav. skin contains flavonoid compounds. This study aims to determine the antiinflammatory power and the effect of variations in the dose of ethanolic extract of the skin of Solanum betaceum Cav on Swiss male strain mice caragenin-induced. The ethanolic extract of Solanum betaceum Cav skin was obtained using remaseration method with 96% ethanol solvent. Antiinflammatory power test using edema formation method with induction of caragenin 1% intraplantar 30 minutes before administration of the test material. Tests were carried out on 25 mice records which were divided into 5 groups namely negative control (0.5% CMC Na suspension), positive control (diclofenac sodium suspension in 0.5% CMC Na dose 7 mg/kgBW) and given suspension respectively. Dutch eggplant skin ethanolic extract in CMC Na 0.5% dose 70 mg/kgBW; 140 mg/kgBW; 280 mg/kgBW orally. The parameters observed were edema thickness measured using calipers at 30 minute intervals for 360 minutes. The results of edema thickness difference are used to calculate the Area Under Curve (AUC) and the percentage of antiinflammatory power (% AIP). Dat a were analyzed statistically with the One Way Anova test and continued by the Post Hoc Test with a 95% confidence level. The results showed that the ethanolic extract of Solanum betaceum Cav skin contains flavonoid compounds and has antiinflammatory power. The greater the dose of ethanolic extract of Solanum betaceum Cav skin, the greater the anti-inflammatory power. Keywords: Solanum betaceum Cav., antinflammation, caragenin


2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Cristan A. Farmer ◽  
Audrey E. Thurm ◽  
Bianca Honnekeri ◽  
Paul Kim ◽  
Susan E. Swedo ◽  
...  

AbstractBrain-derived neurotrophic factor (BDNF), a key peptide in neurocognitive development, has been reported to be elevated in the serum of children with autism spectrum disorder (ASD). In a few studies, however, no differences or the converse have been documented. As a secondary analysis of a natural history study, we examined differences in ELISA serum BDNF between a group of children aged 1 to 9 years (69% white) with ASD (n = 94) and those with typical development (n = 52) or non-ASD developmental delay (n = 21), while accounting for the potential confounding effects of platelet quantity. Platelet counts were measured within 4 h of blood draw using an automated cell counter. Taqman single nucleotide polymorphism (SNP) assays were used to genotype 11 SNPs within the BDNF locus. Unadjusted mean BDNF concentration was higher in children with ASD than in children with typical development (standardized mean difference = 0.23; 95% CI 0.07, 0.38), but not children with non-ASD developmental delay. The magnitude of this difference was reduced after adjusting for platelet count (standardized mean difference = 0.18; 95% CI 0.02, 0.33). Although some BDNF SNPs were related to BDNF concentration, the distributions of these genotypes did not differ across diagnostic groups. This study replicates previous work suggesting that average serum BDNF concentration is higher in ASD compared to typical development, and extends that work by highlighting the potentially confounding role of platelet counts. The etiology of platelet count differences warrants further elucidation. Nonetheless, our results suggest that elevation in BDNF may be partially explained by higher platelet counts in children with ASD, an association that should be considered in future analysis and interpretation.Registration: NCT00298246


Sign in / Sign up

Export Citation Format

Share Document